These are hard times for the biotech sector. Barely a day goes by without layoffs being announced somewhere in Boston or California, and there are still more than 100 biotech stocks worth less than the cash they have in the bank.
Yet there are also very clear signs that the worst might be over for the sector. For investors with a long-term horizon, a recent rally leaves plenty of room for advocate gains.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
